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Background:  Significant cardiac iron overload can occur in end-stage liver disease and may be an underlying cause for cardiovascular events 
observed following liver transplantation (LT), even among patients without hemochromatosis. Serum ferritin is useful to screen patients for total-body 
iron overload, but its role in identifying post-LT cardiac events is not defined. We retrospectively reviewed the association between pre-transplant 
serum ferritin and post-LT survival and cardiovascular (CV) complications.
Methods:  Adult patients with available pre-transplant serum ferritin who underwent LT between 1990 and 2010 were analyzed for the following 
post-LT outcomes: all-cause mortality, death within 1 year, CV complications (non-fatal myocardial infarction, arrhythmias or heart failure), and heart 
failure.
Results:  Of the 763 patients analyzed, median age was 52 years (range 18-77) and 64% were male. Etiologies for LT included hepatitis C (34%), 
hepatitis B (14%), cholestatic (11%), alcohol (10%), and other (31%). Median pre-transplant serum ferritin was 321 mcg/L (range 4.8-27,354). 81 
(10.6%) patients died, including 13 (1.7%) within the first year. 32 (4.2%) patients had CV complications, including 23 (3.0%) with heart failure and 
new ventricular dysfunction (ejection fraction 66±8% pre- vs 37±11% post LT; P<.0001).
Patients who developed heart failure had a significantly higher median ferritin compared to patients who did not develop heart failure (714 vs 320 
mcg/L, P=.04). A serum ferritin cut-off of 1000 mcg/L was significantly associated with post-LT heart failure (5.9% in patients with serum ferritin 
>=1000 mcg/L vs 2.4% with serum ferritin <1000 mcg/L; P<.05). This cut-off had a high negative predictive value (97.6%) but low sensitivity and 
specificity (34.8% and 17.3%, respectively). The other outcomes (all-cause mortality, death within 1 year of LT and post-LT CV complications) were 
not significantly associated with pre-transplant serum ferritin.
Conclusion: Pre-transplant serum ferritin was significantly associated with heart failure after LT. This study supports further cardiac risk 
stratification in patients with pre-transplant serum ferritin >=1000 mcg/L.
